Washington is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Bellevue. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708
Recruiting
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: Hepatocellular Carcinoma
Register for Updates
Trial of Indication-Based Transfusion of Red Blood Cells in ECMO
NCT05405426
Recruiting
TITRE - Trial of Indication-based Transfusion of Red Blood Cells in ECMO, is a multicenter, prospective, randomized clinical trial. The overarching goal of TITRE is to determine whether restricting red blood cell (RBC) transfusion according to an indication-based strategy for those with bleeding and/or deficit of tissue oxygen delivery, compared with transfusion based on center-specific hemoglobin or hematocrit thresholds, can reduce organ dysfunction and improve later neurodevelopment in critic... Read More
Gender:
ALL
Ages:
Between 0 days and 6 years
Trial Updated:
03/24/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Register for Updates
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139
Recruiting
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington
Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: Research Site, Tacoma, Washington
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
NCT04409639
Recruiting
This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Chronic Myelomonocytic Leukemia (CMML)
Register for Updates
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Multicare Health Tacoma-Multicare Institute for Research & Innovation, Tacoma, Washington
Conditions: Stroke, PFO - Patent Foramen Ovale
Register for Updates
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: UW Medicine Diabetes Institute Clinical Research Unit, Seattle, Washington
Conditions: Hypertriglyceridemia
Register for Updates
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: AnaptysBio Investigational Site 10-107, Seattle, Washington
Conditions: Ulcerative Colitis
Register for Updates
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT05960578
Recruiting
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Optimal Timing of Computerized Cognitive Training for Older Intensive Care Unit Survivors
NCT05467410
Recruiting
More than 60% of intensive care unit (ICU) patients are adults ages 60 and older, who are at high risk for ICU-acquired cognitive impairment. After ICU discharge, ICU survivors often experience sleep disturbances and inactivity, and almost 80% of ICU patients experience disturbances in circadian rhythm, which may affect cognitive function. Understanding the optimal, chronotherapeutic timing of cognitive interventions is crucial to promote circadian realignment and cognitive function, and may imp... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/21/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Critical Illness, Cognitive Impairment, Circadian Dysrhythmia, Intensive Care Unit Delirium, Aging, Older People
Register for Updates
Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies
NCT04829136
Recruiting
This clinical trial examines sustained oral fiber supplementation for patients undergoing donor stem cell transplantation for hematological malignancies. Patients undergoing donor stem cell transplantation often develop oral and gastrointestinal damage from chemotherapy, radiotherapy, or graft-versus-host disease. Oral fiber nutrition support may improve overall nutrition, support a normal gut microbiome (bacteria that live in the gut) and/or improve gut function in patients undergoing stem cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Hematopoietic and Lymphatic System Neoplasm
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates